Skip to main content
Top
Published in: Digestive Diseases and Sciences 11/2017

01-11-2017 | Editorial

“First Do No Harm”: Adverse Events from Pharmaceutical Treatment of Gastroparesis and Dyspepsia

Authors: Thomas M. Goodsall, Nicholas J. Talley

Published in: Digestive Diseases and Sciences | Issue 11/2017

Login to get access

Excerpt

Dyspepsia, a symptom that impacts at least 10% of Americans, can be troubling to disabling, impairing work and relationships [1]. Dyspepsia refers to a chronic or recurrent upper gastrointestinal symptom complex presumed to arise from the gastroduodenum rather than the esophagus; epigastric pain or discomfort, fullness after meals, or inability to finish a normal-sized meal (early satiety), and nausea with or without vomiting all are dyspeptic symptoms that can negatively impact the quality of life. If delayed gastric emptying accompanies these symptoms, a diagnostic label of gastroparesis is usually applied [2]. Many other underlying causes of dyspepsia need to be considered, from peptic ulceration including Helicobacter pylori infection to gastroesophageal reflux disease (GERD), biliary tract disease, and rarely esophagogastric cancers, but the most frequent explanation encountered in practice is functional dyspepsia [1]. …
Literature
2.
go back to reference Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol. 2003;98:783–788.CrossRefPubMed Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol. 2003;98:783–788.CrossRefPubMed
3.
go back to reference Pleyer C, Bittner H, Locke GR 3rd, et al. Overdiagnosis of gastro-esophageal reflux disease and underdiagnosis of functional dyspepsia in a USA community. Neurogastroenterol Motil. 2014;26:1163–1171.CrossRefPubMed Pleyer C, Bittner H, Locke GR 3rd, et al. Overdiagnosis of gastro-esophageal reflux disease and underdiagnosis of functional dyspepsia in a USA community. Neurogastroenterol Motil. 2014;26:1163–1171.CrossRefPubMed
4.
go back to reference Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380–1392.CrossRefPubMed Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016;150:1380–1392.CrossRefPubMed
5.
go back to reference Cirillo C, Bessissow T, Desmet AS, Vanheel H, Tack J, Vanden Berghe P. Evidence for neuronal and structural changes in submucous ganglia of patients with functional dyspepsia. Am J Gastroenterol. 2015;110:1205–1215.CrossRefPubMed Cirillo C, Bessissow T, Desmet AS, Vanheel H, Tack J, Vanden Berghe P. Evidence for neuronal and structural changes in submucous ganglia of patients with functional dyspepsia. Am J Gastroenterol. 2015;110:1205–1215.CrossRefPubMed
6.
go back to reference Walker MM, Talley NJ. The role of duodenal inflammation in functional dyspepsia. J Clin Gastroenterol. 2017;51:12–18.CrossRefPubMed Walker MM, Talley NJ. The role of duodenal inflammation in functional dyspepsia. J Clin Gastroenterol. 2017;51:12–18.CrossRefPubMed
7.
go back to reference Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136:1225–1233.CrossRefPubMed Jung HK, Choung RS, Locke GR 3rd, et al. The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009;136:1225–1233.CrossRefPubMed
8.
go back to reference Stein B, Everhart KK, Lacy BE. Gastroparesis: a review of current diagnosis and treatment options. J Clin Gastroenterol. 2015;49:550–558.CrossRefPubMed Stein B, Everhart KK, Lacy BE. Gastroparesis: a review of current diagnosis and treatment options. J Clin Gastroenterol. 2015;49:550–558.CrossRefPubMed
9.
go back to reference Chang JY, Locke GR 3rd, McNally MA, et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol. 2010;105:822–832.CrossRefPubMedPubMedCentral Chang JY, Locke GR 3rd, McNally MA, et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol. 2010;105:822–832.CrossRefPubMedPubMedCentral
10.
go back to reference Talley NJ, Locke GR, Saito YA, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology. 2015;149:340–349.CrossRefPubMedPubMedCentral Talley NJ, Locke GR, Saito YA, et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology. 2015;149:340–349.CrossRefPubMedPubMedCentral
11.
12.
go back to reference Zala AV, Walker MM, Talley NJ. Emerging drugs for functional dyspepsia. Expert Opin Emerg Drugs. 2015;20:221–233.CrossRefPubMed Zala AV, Walker MM, Talley NJ. Emerging drugs for functional dyspepsia. Expert Opin Emerg Drugs. 2015;20:221–233.CrossRefPubMed
13.
go back to reference Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31:11–19.CrossRefPubMed Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31:11–19.CrossRefPubMed
14.
go back to reference Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–416.CrossRefPubMed Gomm W, von Holt K, Thome F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–416.CrossRefPubMed
15.
go back to reference Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0128004.CrossRefPubMedPubMedCentral Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS ONE. 2015;10:e0128004.CrossRefPubMedPubMedCentral
16.
go back to reference Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2017;153:702–710. Nochaiwong S, Ruengorn C, Awiphan R, et al. The association between proton pump inhibitor use and the risk of adverse kidney outcomes: a systematic review and meta-analysis. Nephrol Dial Transplant. 2017;153:702–710.
17.
go back to reference Park CH, Kim EH, Roh YH, Kim HY, Lee SK. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS ONE. 2014;9:e112558.CrossRefPubMedPubMedCentral Park CH, Kim EH, Roh YH, Kim HY, Lee SK. The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis. PLoS ONE. 2014;9:e112558.CrossRefPubMedPubMedCentral
18.
go back to reference Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS ONE. 2012;7:e50836.CrossRefPubMedPubMedCentral Tleyjeh IM, Bin Abdulhak AA, Riaz M, et al. Association between proton pump inhibitor therapy and clostridium difficile infection: a contemporary systematic review and meta-analysis. PLoS ONE. 2012;7:e50836.CrossRefPubMedPubMedCentral
19.
go back to reference Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27:339–347.CrossRefPubMed Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27:339–347.CrossRefPubMed
20.
go back to reference Toh JW, Ong E, Wilson R. Hypomagnesaemia associated with long-term use of proton pump inhibitors. Gastroenterol Rep (Oxf). 2015;3:243–253.CrossRef Toh JW, Ong E, Wilson R. Hypomagnesaemia associated with long-term use of proton pump inhibitors. Gastroenterol Rep (Oxf). 2015;3:243–253.CrossRef
21.
go back to reference Ford AC, Luthra P, Tack J, Boeckxstaens GE, Moayyedi P, Talley NJ. Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut. 2017;66:411–420.CrossRefPubMed Ford AC, Luthra P, Tack J, Boeckxstaens GE, Moayyedi P, Talley NJ. Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut. 2017;66:411–420.CrossRefPubMed
22.
go back to reference Zhong L, Shanahan ER, Raj A, et al. Dyspepsia and the microbiome: time to focus on the small intestine. Gut. 2017;66:1168–1169.CrossRefPubMed Zhong L, Shanahan ER, Raj A, et al. Dyspepsia and the microbiome: time to focus on the small intestine. Gut. 2017;66:1168–1169.CrossRefPubMed
23.
go back to reference Jiang SM, Jia L, Liu J, Shi MM, Xu MZ. Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. World J Gastroenterol. 2016;22:5260–5266.CrossRefPubMedPubMedCentral Jiang SM, Jia L, Liu J, Shi MM, Xu MZ. Beneficial effects of antidepressant mirtazapine in functional dyspepsia patients with weight loss. World J Gastroenterol. 2016;22:5260–5266.CrossRefPubMedPubMedCentral
24.
go back to reference Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107:1361–1369.CrossRefPubMedPubMedCentral Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol. 2012;107:1361–1369.CrossRefPubMedPubMedCentral
25.
go back to reference Group OLoEW. The Oxford 2011 Levels of Evidence.. Oxford Centre for Evidence-Based Medicine. 2011. Group OLoEW. The Oxford 2011 Levels of Evidence.. Oxford Centre for Evidence-Based Medicine. 2011.
Metadata
Title
“First Do No Harm”: Adverse Events from Pharmaceutical Treatment of Gastroparesis and Dyspepsia
Authors
Thomas M. Goodsall
Nicholas J. Talley
Publication date
01-11-2017
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 11/2017
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-017-4757-x

Other articles of this Issue 11/2017

Digestive Diseases and Sciences 11/2017 Go to the issue